- $1.51bn
- $2.01bn
- $614.38m
- 49
- 35
- 99
- 64
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.66 | ||
| PEG Ratio (f) | 0.14 | ||
| EPS Growth (f) | 328.84% | ||
| Dividend Yield (f) | 2.29% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.74 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 31.58 | ||
| Price to Sales | 2.46 | ||
| EV to EBITDA | 32.98 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.63% | ||
| Return on Equity | -4.82% | ||
| Operating Margin | -1.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 208.47 | 216.14 | 316.38 | 486.82 | 614.38 | 769.08 | 828.59 | 24.36% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +10.27 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Directors
- Patrick Walsh CHM (60)
- Nikhil Lalwani PRE (44)
- Stephen Carey CFO (51)
- Chad Gassert SVP
- Ori Gutwerg SVP (47)
- James Marken SVP (58)
- Davinder Singh GMG
- Muthusamy Shanmugam OTH (54)
- Christopher Mutz OTH (50)
- Robert Brown IND (70)
- Thomas Haughey IND (57)
- David Nash IND (65)
- Antonio Pera IND (63)
- Jeanne Thoma IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 11th, 2001
- Public Since
- May 4th, 2000
- No. of Shareholders
- 358
- No. of Employees
- 897
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 21,611,837
- Address
- 210 Main Street West, BAUDETTE, 56623
- Web
- https://www.anipharmaceuticals.com/
- Phone
- +1 2186343500
- Contact
- Lisa Wilson
- Auditors
- EisnerAmper LLP
Upcoming Events for ANIP
Q1 2025 ANI Pharmaceuticals Inc Earnings Release
ANI Pharmaceuticals Inc Annual Shareholders Meeting
ANI Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 ANI Pharmaceuticals Inc Earnings Release
Similar to ANIP
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
Avidity Biosciences
NASDAQ Global Market
FAQ
What is the ANI Pharmaceuticals share price?
As of Today at 19:15 UTC, shares in ANI Pharmaceuticals are trading at $69.82. This share price information is delayed by 15 minutes.
How has the ANI Pharmaceuticals share price performed this year?
Shares in ANI Pharmaceuticals last closed at $69.82 and the price had moved by +7.5% over the past 365 days. In terms of relative price strength the ANI Pharmaceuticals share price has underperformed the S&P500 Index by -0.78% over the past year.
What are the analyst and broker recommendations for ANI Pharmaceuticals?
The overall consensus recommendation for ANI Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the ANI Pharmaceuticals dividend yield?
ANI Pharmaceuticals does not currently pay a dividend.
Does ANI Pharmaceuticals pay a dividend?
ANI Pharmaceuticals does not currently pay a dividend.
When does ANI Pharmaceuticals next pay dividends?
ANI Pharmaceuticals does not currently pay a dividend.
How do I buy ANI Pharmaceuticals shares?
To buy shares in ANI Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ANI Pharmaceuticals?
As of the previous close price of $69.82, shares in ANI Pharmaceuticals had a market capitalisation of $1.51bn.
Where are ANI Pharmaceuticals shares listed?
Here are the trading details for ANI Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ANIP
What kind of share is ANI Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum ANI Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ANI Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in ANI Pharmaceuticals is $81.43. That is 16.63% above the last closing price of $69.82.
Analysts covering ANI Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $6.34 for the next financial year.
Find out moreWhat is the trend in the ANI Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ANI Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +26.18%.
As of the last closing price of $69.82, shares in ANI Pharmaceuticals were trading +16.23% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ANI Pharmaceuticals PE Ratio?
The ANI Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 10.66. The shares last closed at $69.82.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ANI Pharmaceuticals?
ANI Pharmaceuticals' management team is headed by:
- Patrick Walsh - CHM
- Nikhil Lalwani - PRE
- Stephen Carey - CFO
- Chad Gassert - SVP
- Ori Gutwerg - SVP
- James Marken - SVP
- Davinder Singh - GMG
- Muthusamy Shanmugam - OTH
- Christopher Mutz - OTH
- Robert Brown - IND
- Thomas Haughey - IND
- David Nash - IND
- Antonio Pera - IND
- Jeanne Thoma - IND